RyMed Technologies

RyMed Technologies, founded in 2003 and headquartered in Franklin, Tennessee, is a private medical device company commercializing its proprietary InVision-Plus® needle-free IV connectors. Its core technology, Neutral Advantage Technology, is built around a '10-Point Standard' that addresses key failure points in IV therapy, such as infection and occlusion, through a fail-safe engineering design. The company is revenue-generating with a commercial-stage product line, recently expanding into pediatric and NICU populations. RyMed operates in the competitive vascular access segment, positioning its products as a premium standard for safety and clinical efficacy.

Neutral Advantage Technology: A proprietary 10-Point Standard engineering framework for needle-free IV connectors. It integrates features like a swabbable septum, seal integrity, straight-through fluid pathway, zero dead space, and neutral fluid displacement to inhibit bacterial migration and blood reflux, aiming to prevent catheter-related bloodstream infections and thrombotic occlusions.

RyMed competes in the crowded needle-free connector market against major players like BD (Q-Syte), ICU Medical (Clave), and Baxter. Its strategy is to differentiate on a comprehensive, engineering-based safety standard (10-Point) rather than price, positioning itself as a premium solution for infection and occlusion prevention targeted at value-conscious hospitals.